Trastuzumab Deruxtecan in Previously Treated HER2-Low

trastuzumab  Trastuzumab was developed by Genentech Inc as a recombinant humanized monoclonal antibody directed against the Interpretation We have shown that 6-month trastuzumab treatment is non-inferior to 12-month treatment in patients with HER2-positive early

ของยาตัวใหม่ที่กระตุ้นให้เกิดการแพ้ยาในขณะที่ยาต้นแบบไ ม่มี เป็นต้น Trastuzumab เป็น humanized monoclonal antibody ที่ออกฤทธิ์ต้าน HER2 ซึ่งเป็น growth factor receptor Trastuzumab emtansine binds to the HER2 receptor's sub-domain IV and goes into the cell by receptor-mediated endocytosis Lysosomes degrade trastuzumab

Trastuzumab deruxtecan is an effective new treatment for patients with HER2-positive metastatic breast cancer who have been previously treated Common side effects of pertuzumab and trastuzumab · Risk of infection · Bruising and bleeding · Anaemia · Effects on the heart